Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHRISTOPHER MARC MAISEL

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1275575185
CMS profile
57298
Location
DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$130,346.52

183 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 183 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHRISTOPHER MARC MAISEL

NPI 1275575185 · CMS profile ID 57298

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 183 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1275575185?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHRISTOPHER MARC MAISEL, NPI 1275575185, CMS profile ID 57298. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 183 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1275575185?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). CHRISTOPHER MARC MAISEL, NPI 1275575185, CMS profile ID 57298. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 183 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1275575185?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
CHRISTOPHER MARC MAISEL, NPI 1275575185, CMS profile ID 57298, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 183 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1275575185?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

183 matching records · $130,346.52 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 183 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 183.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Celgene Corporation $13.3406/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016006043 CMS
ABBVIE INC. $33.9406/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997819765 CMS
E.R. Squibb & Sons, L.L.C. $2,664.0006/06/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016006011 CMS
Incyte Corporation $24.5406/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044494841 CMS
Janssen Scientific Affairs, LLC $585.0006/06/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988439511 CMS
Blueprint Medicines Corporation $20.5706/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051262093 CMS
Emmaus Medical, Inc. $17.8405/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014084827 CMS
ADC Therapeutics America, Inc. $94.7605/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053791231 CMS
Novartis Pharmaceuticals Corporation $33.7505/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992858555 CMS
GENZYME CORPORATION $96.1905/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050087831 CMS
Gilead Sciences, Inc. $34.0605/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025490935 CMS
Gilead Sciences, Inc. $2,570.0005/17/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1035503813 CMS
Janssen Biotech, Inc. $7.8605/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988377905 CMS
Janssen Biotech, Inc. $15.0005/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988377915 CMS
Janssen Biotech, Inc. $3,575.0005/16/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988377927 CMS
Janssen Biotech, Inc. $20.0005/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988377936 CMS
Janssen Biotech, Inc. $22.8105/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988377989 CMS
Seagen Inc. $15.0905/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995643959 CMS
Gilead Sciences, Inc. $124.9905/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025507987 CMS
Gilead Sciences, Inc. $45.0005/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025536061 CMS
JAZZ PHARMACEUTICALS INC. $20.4805/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058399665 CMS
Ipsen Biopharmaceuticals, Inc $24.6305/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045407851 CMS
AstraZeneca Pharmaceuticals LP $18.0305/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016002389 CMS
ADC Therapeutics America, Inc. $14.4105/02/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053791163 CMS
ADC Therapeutics America, Inc. $15.0005/02/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053791167 CMS
Emmaus Medical, Inc. $22.6604/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014084821 CMS
MorphoSys, US Inc. $15.1904/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060324505 CMS
ADC Therapeutics America, Inc. $123.6904/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053791157 CMS
ADC Therapeutics America, Inc. $3,100.0004/20/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053791151 CMS
ABBVIE INC. $28.3004/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997819763 CMS
ADC Therapeutics America, Inc. $1,860.0004/18/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053791145 CMS
Incyte Corporation $21.8504/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044494783 CMS
ADC Therapeutics America, Inc. $3.2804/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053791139 CMS
ADC Therapeutics America, Inc. $28.7004/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053791193 CMS
ADC Therapeutics America, Inc. $149.9904/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053791199 CMS
SOBI, INC $23.1704/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038089987 CMS
Janssen Biotech, Inc. $412.5004/12/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988377887 CMS
Janssen Biotech, Inc. $1,562.5004/11/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988377897 CMS
Janssen Biotech, Inc. $1,562.5004/11/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988377942 CMS
CTI BioPharma Corp. $24.1904/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039689167 CMS
ADC Therapeutics America, Inc. $153.1704/05/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053791127 CMS
ADC Therapeutics America, Inc. $154.1704/05/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053791133 CMS
Blueprint Medicines Corporation $1,232.0004/05/2023 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051262221 CMS
Blueprint Medicines Corporation $1,232.0004/05/2023 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051262261 CMS
ADC Therapeutics America, Inc. $3,100.0004/04/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053791121 CMS
ADC Therapeutics America, Inc. $3,100.0003/30/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053791109 CMS
ADC Therapeutics America, Inc. $121.8203/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053791117 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.0703/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055468139 CMS
Blueprint Medicines Corporation $4,620.0003/29/2023 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051262197 CMS
Blueprint Medicines Corporation $129.6903/29/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051262201 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $108,326.39 112
PY2020 $106,155.30 82
PY2021 $69,690.31 69
PY2022 $146,092.96 136
PY2023 $130,346.52 183
PY2024 $86,640.50 107
PY2025 $65,767.30 65

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $290,691.51 36
PY2024 Principal investigator $199,066.85 34
PY2023 Recipient $3,200.00 6
PY2023 Principal investigator $297,776.23 31
PY2022 Recipient $940.00 1
PY2022 Principal investigator $188,098.10 14
PY2021 Principal investigator $85,002.65 4
PY2020 Principal investigator $4,825.00 1
PY2019 Principal investigator $5,050.59 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

36 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $4,238.00 12/31/2025 Non-covered Recipient Entity
Baylor Scott White Research
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228747981
Principal investigator 1 PFIZER INC. $2,603.45 12/19/2025 Non-covered Recipient Entity
Baylor Scott White Research Institute
MAGNETISMM3 AN OPENLABEL MULTICENTER NONRANDOMIZED PHASE 2 STUDY OF ELRANATAMAB PF06863135 MONOTHERAPY IN PARTICIPANTS WITH MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR ONE IMMUNOMODULATORY DRUG AND ONE ANTICD38 ANTIBODY No dispute reported 06/30/2026 1228725716
Principal investigator 1 PFIZER INC. $3,539.90 12/10/2025 Non-covered Recipient Entity
Baylor Scott White Research
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228736611
Principal investigator 1 PFIZER INC. $107.90 12/09/2025 Non-covered Recipient Entity
Baylor Scott White Research Institute
MAGNETISMM3 AN OPENLABEL MULTICENTER NONRANDOMIZED PHASE 2 STUDY OF ELRANATAMAB PF06863135 MONOTHERAPY IN PARTICIPANTS WITH MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR ONE IMMUNOMODULATORY DRUG AND ONE ANTICD38 ANTIBODY No dispute reported 06/30/2026 1228745881
Principal investigator 1 PFIZER INC. $15,568.02 12/03/2025 Non-covered Recipient Entity
Baylor Scott White Research
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228731298
Principal investigator 1 PFIZER INC. $390.00 11/26/2025 Non-covered Recipient Entity
Baylor Scott White Research
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228722612
Principal investigator 1 PFIZER INC. $7,777.90 11/19/2025 Non-covered Recipient Entity
Baylor Scott White Research
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228730212
Principal investigator 1 PFIZER INC. $27,688.01 10/22/2025 Non-covered Recipient Entity
Baylor Scott White Research
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228729803
Principal investigator 1 PFIZER INC. $215.80 10/22/2025 Non-covered Recipient Entity
Baylor Scott White Research Institute
MAGNETISMM3 AN OPENLABEL MULTICENTER NONRANDOMIZED PHASE 2 STUDY OF ELRANATAMAB PF06863135 MONOTHERAPY IN PARTICIPANTS WITH MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR ONE IMMUNOMODULATORY DRUG AND ONE ANTICD38 ANTIBODY No dispute reported 06/30/2026 1228741468
Principal investigator 1 PFIZER INC. $1,452.10 10/15/2025 Non-covered Recipient Entity
Baylor Scott White Research
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228739875
Principal investigator 1 PFIZER INC. $5,215.60 10/09/2025 Non-covered Recipient Entity
Baylor Scott White Research
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228741950
Principal investigator 1 PFIZER INC. $9,076.60 09/24/2025 Non-covered Recipient Entity
Baylor Scott White Research
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228757639
Principal investigator 1 PFIZER INC. $2,378.00 09/17/2025 Non-covered Recipient Entity
Baylor Scott White Research
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228754115
Principal investigator 1 PFIZER INC. $22,392.42 08/22/2025 Non-covered Recipient Entity
Baylor Scott White Research
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228768287
Principal investigator 1 PFIZER INC. $14,336.05 08/20/2025 Non-covered Recipient Entity
Baylor Scott White Research
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228767131
Principal investigator 1 PFIZER INC. $2,405.00 08/06/2025 Non-covered Recipient Entity
Baylor Scott White Research
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228786451
Principal investigator 1 PFIZER INC. $15,142.65 07/25/2025 Non-covered Recipient Entity
Baylor Scott White Research
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228781641
Principal investigator 1 PFIZER INC. $12,354.19 07/16/2025 Non-covered Recipient Entity
Baylor Scott White Research
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228772697
Principal investigator 1 PFIZER INC. $22,339.20 07/02/2025 Non-covered Recipient Entity
Baylor Scott White Research Institute
MAGNETISMM3 AN OPENLABEL MULTICENTER NONRANDOMIZED PHASE 2 STUDY OF ELRANATAMAB PF06863135 MONOTHERAPY IN PARTICIPANTS WITH MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR ONE IMMUNOMODULATORY DRUG AND ONE ANTICD38 ANTIBODY No dispute reported 06/30/2026 1228765091
Principal investigator 1 PFIZER INC. $7,316.40 07/02/2025 Non-covered Recipient Entity
Baylor Scott White Research
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228781957
Principal investigator 1 PFIZER INC. $2,107.60 06/27/2025 Non-covered Recipient Entity
Baylor Scott White Research Institute
MAGNETISMM3 AN OPENLABEL MULTICENTER NONRANDOMIZED PHASE 2 STUDY OF ELRANATAMAB PF06863135 MONOTHERAPY IN PARTICIPANTS WITH MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR ONE IMMUNOMODULATORY DRUG AND ONE ANTICD38 ANTIBODY No dispute reported 06/30/2026 1228774734
Principal investigator 1 PFIZER INC. $35,114.95 06/26/2025 Non-covered Recipient Entity
Baylor Scott White Research
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228790808
Principal investigator 1 PFIZER INC. $3,539.90 05/30/2025 Non-covered Recipient Entity
Baylor Scott White Research
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228781902
Principal investigator 1 PFIZER INC. $22,349.28 05/23/2025 Non-covered Recipient Entity
Baylor Scott White Research
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228773213
Principal investigator 1 PFIZER INC. $3,032.55 05/21/2025 Non-covered Recipient Entity
Baylor Scott White Research
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228775846
Principal investigator 1 PFIZER INC. $16,525.80 05/14/2025 Non-covered Recipient Entity
Baylor Scott White Research
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228762410
Principal investigator 1 PFIZER INC. $4,188.51 05/07/2025 Non-covered Recipient Entity
Baylor Scott White Research
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228762785
Principal investigator 1 PFIZER INC. $215.80 04/09/2025 Non-covered Recipient Entity
Baylor Scott White Research Institute
MAGNETISMM3 AN OPENLABEL MULTICENTER NONRANDOMIZED PHASE 2 STUDY OF ELRANATAMAB PF06863135 MONOTHERAPY IN PARTICIPANTS WITH MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR ONE IMMUNOMODULATORY DRUG AND ONE ANTICD38 ANTIBODY No dispute reported 06/30/2026 1228779998
Principal investigator 1 PFIZER INC. $4,393.01 04/09/2025 Non-covered Recipient Entity
Baylor Scott White Research
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228797427
Principal investigator 1 PFIZER INC. $1,553.50 04/01/2025 Non-covered Recipient Entity
Baylor Scott White Research
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228780181
Principal investigator 1 PFIZER INC. $722.50 03/25/2025 Non-covered Recipient Entity
Baylor Scott White Research
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228779405
Principal investigator 1 PFIZER INC. $2,000.00 03/12/2025 Non-covered Recipient Entity
Baylor Scott White Research
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228783437
Principal investigator 1 PFIZER INC. $107.90 03/12/2025 Non-covered Recipient Entity
Baylor Scott White Research Institute
MAGNETISMM3 AN OPENLABEL MULTICENTER NONRANDOMIZED PHASE 2 STUDY OF ELRANATAMAB PF06863135 MONOTHERAPY IN PARTICIPANTS WITH MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR ONE IMMUNOMODULATORY DRUG AND ONE ANTICD38 ANTIBODY No dispute reported 06/30/2026 1228794271
Principal investigator 1 PFIZER INC. $4,091.01 03/05/2025 Non-covered Recipient Entity
Baylor Scott White Research
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228780842
Principal investigator 1 PFIZER INC. $4,466.01 02/06/2025 Non-covered Recipient Entity
Baylor Scott White Research
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228757573
Principal investigator 1 PFIZER INC. $9,746.00 01/15/2025 Non-covered Recipient Entity
Baylor Scott White Research
A RANDOMIZED 2ARM PHASE 3 STUDY OF ELRANATAMAB PF06863135 VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEMCELL TRANSPLANTATION No dispute reported 06/30/2026 1228800921